Saxenda day 2 nausea claims: what GLP-1 side effects actually look like

What did @kellyramirez30 actually say?

On day two of restarting Saxenda (liraglutide 0.6 mg), Kelly reported mild nausea that she was managing with "snacks and food," noticed early appetite reduction, switched injection sites to her arm for the first time, and committed to pairing the medication with jogging. She was clear that she does not want to "fully rely" on the medication and sees it as a tool, not a cure.

She did not make dramatic weight loss claims, did not advise anyone on dosing, and did not promote any specific product. For a day-two GLP-1 video, the framing was more grounded than most of what circulates under the #glp1community hashtag.

Does the science back this up?

Mostly, yes. The nausea timeline and the strategy she is using to manage it are consistent with clinical data. The appetite suppression she is already noticing by day two is physiologically plausible, and her instinct to add exercise is supported by outcome research.

Nausea is the most common side effect of liraglutide, reported in roughly 38 to 40 percent of patients in the SCALE Obesity and Prediabetes trial (Davies et al., 2015, New England Journal of Medicine). It typically peaks in the first few weeks at each dose escalation and diminishes over time. Eating small, low-fat snacks before or after injection, which is essentially what Kelly is doing, is a clinically recognized mitigation strategy. Her appetite suppression on day two is early but not implausible: liraglutide acts on GLP-1 receptors in the hypothalamus and brainstem within hours of injection, so subjective appetite changes can appear before any meaningful weight loss does.

What did they get wrong (or right)?

Kelly got the fundamentals right. She got one small detail wrong, and there is one omission worth flagging.

The arm injection is fine. All approved subcutaneous injection sites, abdomen, thigh, and upper arm, are supported in Saxenda's prescribing information. Some patients do report less discomfort in the arm, likely due to differences in subcutaneous fat depth, so her anecdotal observation is not surprising.

The omission: she does not mention rotating injection sites within each region, which matters for preventing lipohypertrophy, a localized buildup of fatty tissue that can impair drug absorption over time (Blanco et al., 2013, Diabetes Care). If she is now adding the arm to her rotation, that is actually good practice, but viewers watching this as a how-to guide would not know to vary the exact spot each time.

The hashtag misspelling of "semiglutide" instead of semaglutide is cosmetic and harmless, but worth noting: Saxenda contains liraglutide, not semaglutide. These are different GLP-1 receptor agonists with different half-lives, dosing schedules, and clinical profiles. The conflation in the hashtags could mislead viewers who are comparing medications.

What should you actually know?

A few things that Kelly's video does not cover but that anyone starting a GLP-1 should understand.

• Nausea that is manageable with snacks is normal at 0.6 mg. The standard Saxenda protocol escalates the dose monthly, and nausea tends to worsen with each increase. What is mild now may not stay mild at 1.8 mg or 3.0 mg.
• Exercise genuinely improves outcomes. A 2023 meta-analysis (Lundgren et al., 2023, Obesity Reviews) found that combining GLP-1 receptor agonist therapy with structured exercise preserved lean muscle mass better than medication alone. Kelly's instinct to jog is not just motivational content; it is clinically sound.
• Liraglutide and semaglutide are not the same drug. Saxenda is liraglutide, a once-daily injection. Semaglutide is the active ingredient in Ozempic and Wegovy, which are weekly injections with different efficacy data. Mixing up hashtags is one thing; mixing up medications is a real patient safety issue.
• "Feeling great" on day two does not predict the full experience. The dose escalation schedule exists precisely because side effects intensify. Viewers should not treat a positive day-two update as a reliable preview of the full course.